慢性肺病患者经导管或外科主动脉瓣置换的短期与长期结局:德国主动脉瓣注册分析
基于德国主动脉瓣注册(GARY)2014–2015及2018–2019随访数据,分析慢性肺病(CLD)患者行TAVI或SAVR的结局差异。倾向评分加权亚组1385例CLD患者显示,30天死亡率两组相似(SAVR 2.3%,TAVI 3.8%,P=.964),5年生存率TAVI(44.6%)显著低于SAVR(56.7%),P=.029。
要点
- CLD患者术后并发症或死亡风险高于无CLD患者。
- CLD患者30天死亡率TAVI与SAVR相似(2.3% vs 3.8%,P=.964)。
- 5年生存率TAVI低于SAVR(44.6% vs 56.7%,P=.029)。
核心结论
- CLD患者行SAVR或TAVI术后并发症或死亡风险均高于无CLD患者。
- 5年后TAVI与SAVR患者报告结局相似。
研究设计与样本
- 基于德国主动脉瓣注册(GARY)2014–2015及2018–2019随访数据的分析。
- 对1385例CLD患者行倾向评分加权分析比较TAVI与SAVR结局。
主要发现
- CLD患者较无CLD患者病情更重,但观察到的30天死亡率低于3种风险评分预测值。
- 两种治疗组中CLD患者长期生存率均低于无CLD患者。
- 倾向评分加权亚组中30天死亡率SAVR 2.3%、TAVI 3.8%,P=.964。
- 5年随访生存率TAVI 44.6%显著低于SAVR 56.7%,P=.029。
临床怎么用
- CLD患者选择TAVI或SAVR需权衡短期安全性与长期生存。
- CLD患者术后应加强并发症与死亡风险评估。
局限性
- 可能存在有利于SAVR的选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Data from the German Aortic Valve Registry (GARY) were analysed to determine whether there are differences between patients with and without chronic lung disease (CLD) undergoing transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR) and whether TAVI or SAVR is more beneficial in patients with preexisting CLD. METHODS: Follow-up data from GARY registry patients treated from 2014 to 2015 and from 2018 to 2019 were incorporated in the analysis. Demographic results for each of the 2 treatment modalities were evaluated, and patients with and without CLD were compared. In a second step, variables that would have influenced the treatment decision in CLD patients in direction of either SAVR or TAVI were accounted for in the adjusted analysis. This led to a subgroup of 1385 patients with CLD that was subjected to propensity score weighted analysis to compare outcomes of TAVI and SAVR. RESULTS: After exclusion, 11 457 SAVR patients and 2378 TAVI patients were analysed. CLD patients were sicker than patients without CLD, although the observed 30-day mortality was lower than expected by 3 risk scores. Accordingly, long-term survival in CLD patients was lower in both treatment groups than in patients without CLD. Thirty-day mortality was similar in the 2 treatment groups (SAVR 2.3%, TAVI 3.8%, P = .964) in spite of a possible selection bias in favour of SAVR. During a 5-year follow-up, survival after TAVI (44.6%) was significantly lower than after SAVR (56.7%), P = .029. CONCLUSIONS: Patients with CLD undergoing SAVR or TAVI are generally at higher risk for complications or death after the procedure than patients without CLD. After 5 years, patient-reported outcomes were similar in TAVI and in SAVR patients.
引用
- Böning A, Balaban U, Herrmann E, et al. Short- and Long-Term Outcomes After Transcatheter or Surgical Aortic Valve Replacement in Patients With Chronic Lung Disease: An Analysis From the German Aortic Valve Registry. Interdiscip Cardiovasc Thorac Surg. 2025. PMID: 40824048. doi:10.1093/icvts/ivaf189
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。